{"id":"W2889573684","doi":"10.1161/strokeaha.118.022128","title":"Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke","year":2018,"lang":"en","type":"review","venue":"Stroke","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotchkiss Brain Institute; University of Calgary","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; National Institute of Neurological Disorders and Stroke; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Belvoir Media Group; Medicines Company; Regado Biosciences; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; St. Jude Medical; Duke Clinical Research Institute; Eisai; Boston VA Research Institute; Boston Scientific Corporation; Idorsia Pharmaceuticals; Bristol-Myers Squibb; Cleveland Clinic; Massachusetts General Hospital; Eli Lilly and Company; Amgen; Pfizer; Patient-Centered Outcomes Research Institute; Sanofi; American Heart Association","keywords":"Medicine; Dabigatran; Modified Rankin Scale; Rivaroxaban; Vitamin K antagonist; Interquartile range; Stroke (engine); Warfarin; Apixaban; Intracerebral hemorrhage; Direct thrombin inhibitor; Anesthesia; Tissue plasminogen activator; Internal medicine; Idarucizumab; Fibrinolytic agent; Odds ratio; Atrial fibrillation; Ischemic stroke; Ischemia; Glasgow Coma Scale","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002171077,0.0004337037,0.002144162,0.007717417,0.0002892215,0.001141525,0.000619585,0.0009021561,0.001637322],"category_scores_gemma":[0.01107882,0.0002947263,0.001847937,0.008396906,0.000380989,0.001100278,0.0003866559,0.0004232524,0.0002234611],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006065004,"about_ca_system_score_gemma":0.002101935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001984831,"about_ca_topic_score_gemma":0.004356519,"domain_scores_codex":[0.9976469,0.0005483704,0.00115896,0.0002952523,0.0002990941,0.0000514627],"domain_scores_gemma":[0.984869,0.009302825,0.00455918,0.0001473923,0.00098581,0.0001357319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001183526,0.0001018072,0.07834372,0.6450933,0.007770338,0.002451767,0.0004380049,0.0002093723,0.001170963,0.0005122208,0.004341444,0.2583835],"study_design_scores_gemma":[0.0006802621,0.001681309,0.244413,0.5917425,0.06175222,0.02096584,0.001552958,0.0003981519,0.001936224,0.001242831,0.07352601,0.000108621],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006372667,0.9925069,0.00007266502,0.0002269478,0.00006312379,0.00002953489,0.000303931,0.000002536764,0.0004215785],"genre_scores_gemma":[0.09241353,0.9053417,0.0005441496,0.000606964,0.000343442,0.00008241609,0.0005479688,0.000003255782,0.0001166328],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007717417,"threshold_uncertainty_score":0.01148182,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02628047061260643,"score_gpt":0.3058567168630562,"score_spread":0.2795762462504498,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}